Key facts
- Noema Pharma’s last known valuation is $228.8M (Dec 2024).
- It has raised $209.8M; the latest was Later Stage VC ($146.9M) in Dec 2024.
- Notable investors include Sofinnova Partners, Polaris Partners, The Invus Group, Forbion, EQT Life Sciences — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Noema Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Noema Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Noema Pharma
Operator of a biotechnology company intended to address the disabling symptoms in orphan conditions of the central nervous system. The company offers novel therapies for conditions affecting the nervous system including diseases characterized by imbalanced neuronal networks, enabling medical professionals to improve quality of life and patient outcomes.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2019
- Employees
- 33
- Website
- noemapharma.com/
- Ownership
- Privately Held (backing)
Noema Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Noema Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Noema Pharma in its N-PORT filings yet. We sweep new filings monthly.